LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 240

Search options

  1. Article ; Online: The first human acute myeloid leukemia genome ever fully sequenced.

    Falini, Brunangelo

    Haematologica

    2024  Volume 109, Issue 1, Page(s) 1–2

    MeSH term(s) Humans ; Base Sequence ; Leukemia, Myeloid, Acute/genetics
    Language English
    Publishing date 2024-01-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.282118
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.

    Falini, Brunangelo

    American journal of hematology

    2023  Volume 98, Issue 9, Page(s) 1452–1464

    Abstract: The nucleophosmin (NPM1) gene encodes for a multifunctional chaperone protein that is localized in the nucleolus but continuously shuttles between the nucleus and cytoplasm. NPM1 mutations occur in about one-third of AML, are AML-specific, usually ... ...

    Abstract The nucleophosmin (NPM1) gene encodes for a multifunctional chaperone protein that is localized in the nucleolus but continuously shuttles between the nucleus and cytoplasm. NPM1 mutations occur in about one-third of AML, are AML-specific, usually involve exon 12 and are frequently associated with FLT3-ITD, DNMT3A, TET2, and IDH1/2 mutations. Because of its unique molecular and clinico-pathological features, NPM1-mutated AML is regarded as a distinct leukemia entity in both the International Consensus Classification (ICC) and the 5th edition of the World Health Organization (WHO) classification of myeloid neoplasms. All NPM1 mutations generate leukemic mutants that are aberrantly exported in the cytoplasm of the leukemic cells and are relevant to the pathogenesis of the disease. Here, we focus on recently identified functions of the NPM1 mutant at chromatin level and its relevance in driving HOX/MEIS gene expression. We also discuss yet controversial issues of the ICC/WHO classifications, including the biological and clinical significance of therapy-related NPM1-mutated AML and the relevance of blasts percentage in defining NPM1-mutated AML. Finally, we address the impact of new targeted therapies in NPM1-mutated AML with focus on CAR T cells directed against NPM1/HLA neoepitopes, as well as XPO1 and menin inhibitors.
    MeSH term(s) Humans ; Nucleophosmin ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/therapy ; Leukemia, Myeloid, Acute/pathology ; Mutation ; Cytoplasm
    Chemical Substances Nucleophosmin (117896-08-9) ; Nuclear Proteins
    Language English
    Publishing date 2023-06-15
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26989
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Acute myeloid leukemia risk models: Where do we stand?

    Falini, Brunangelo

    American journal of hematology

    2022  Volume 97, Issue 9, Page(s) 1124–1126

    MeSH term(s) Humans ; Leukemia, Myeloid, Acute/epidemiology ; Remission Induction
    Language English
    Publishing date 2022-08-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26666
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Generation of the first monoclonal antibody using mouse hybridomas.

    Falini, Brunangelo

    Haematologica

    2022  Volume 107, Issue 12, Page(s) 2772–2773

    MeSH term(s) Mice ; Animals ; Hybridomas ; Antibodies, Monoclonal/therapeutic use
    Chemical Substances Antibodies, Monoclonal
    Language English
    Publishing date 2022-12-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.281671
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: NPM1-mutated myeloid neoplasm with low percentage of blasts.

    Falini, Brunangelo / Chiusolo, Patrizia / Fianchi, Luana / Pagano, Livio

    American journal of hematology

    2024  

    Language English
    Publishing date 2024-02-23
    Publishing country United States
    Document type Case Reports
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.27260
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: B-cell prolymphocytic leukemia after COVID-19 infection.

    Falini, Brunangelo / Lazzi, Stefano

    Blood

    2023  Volume 141, Issue 14, Page(s) 1777

    MeSH term(s) Humans ; Leukemia, Prolymphocytic, B-Cell ; COVID-19/complications
    Language English
    Publishing date 2023-03-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2023019816
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.

    Falini, Brunangelo / Martelli, Maria Paola

    American journal of hematology

    2023  Volume 98, Issue 3, Page(s) 481–492

    Abstract: Several editions of the World Health Organization (WHO) classifications of lympho-hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for diagnosis. Since the 4th WHO edition, here referred as WHO-HAEM4, significant clinico- ...

    Abstract Several editions of the World Health Organization (WHO) classifications of lympho-hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for diagnosis. Since the 4th WHO edition, here referred as WHO-HAEM4, significant clinico-pathological, immunophenotypic, and molecular advances have been made in the field of myeloid neoplasms, which have contributed to refine diagnostic criteria, to upgrade entities previously defined as provisional and to identify new entities. This process has resulted in two recent classification proposals of myeloid neoplasms: the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO-HAEM5). In this paper, we review and compare the two classifications in terms of diagnostic criteria and entity definition, with a focus on adult myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML). The goal is to provide a tool to facilitate the work of pathologists, hematologists and researchers involved in the diagnosis and treatment of these hematological malignancies.
    MeSH term(s) Adult ; Humans ; Consensus ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/pathology ; Leukemia, Myeloid, Acute/diagnosis ; Myeloproliferative Disorders/pathology ; Hematologic Neoplasms ; World Health Organization
    Language English
    Publishing date 2023-01-05
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26812
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Diffuse large B-cell lymphoma of the testis.

    Falini, Brunangelo / Lazzi, Stefano

    Blood

    2022  Volume 140, Issue 24, Page(s) 2645

    MeSH term(s) Male ; Humans ; Testis/pathology ; Lymphoma, Large B-Cell, Diffuse/pathology ; Testicular Neoplasms/pathology
    Language English
    Publishing date 2022-12-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2022018344
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.

    Falini, Brunangelo / Dillon, Richard

    Blood cancer discovery

    2023  Volume 5, Issue 1, Page(s) 8–20

    Abstract: NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of adult AML. NPM1-mutated AML is recognizable by molecular techniques and immunohistochemistry, which, when combined, can solve difficult diagnostic problems (including ... ...

    Abstract NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of adult AML. NPM1-mutated AML is recognizable by molecular techniques and immunohistochemistry, which, when combined, can solve difficult diagnostic problems (including identification of myeloid sarcoma and NPM1 mutations outside exon 12). According to updated 2022 European LeukemiaNet (ELN) guidelines, determining the mutational status of NPM1 (and FLT3) is a mandatory step for the genetic-based risk stratification of AML. Monitoring of measurable residual disease (MRD) by qRT-PCR, combined with ELN risk stratification, can guide therapeutic decisions at the post-remission stage. Here, we review the criteria for appropriate diagnosis and molecular monitoring of NPM1-mutated AML.
    Significance: NPM1-mutated AML represents a distinct entity in the 2022 International Consensus Classification and 5th edition of World Health Organization classifications of myeloid neoplasms. The correct diagnosis of NPM1-mutated AML and its distinction from other AML entities is extremely important because it has clinical implications for the management of AML patients, such as genetic-based risk stratification according to 2022 ELN. Monitoring of MRD by qRT-PCR, combined with ELN risk stratification, can guide therapeutic decisions at the post-remission stage, e.g., whether or not to perform allogeneic hematopoietic stem cell transplantation.
    MeSH term(s) Adult ; Humans ; Nuclear Proteins/genetics ; Nucleophosmin ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/therapy ; Mutation ; Risk Factors
    Chemical Substances Nuclear Proteins ; Nucleophosmin (117896-08-9)
    Language English
    Publishing date 2023-11-02
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3028898-8
    ISSN 2643-3249 ; 2643-3230
    ISSN (online) 2643-3249
    ISSN 2643-3230
    DOI 10.1158/2643-3230.BCD-23-0144
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Pediatric large B-cell lymphoma with 11q aberration.

    Falini, Brunangelo / Lazzi, Stefano

    Blood

    2022  Volume 140, Issue 24, Page(s) 2644

    MeSH term(s) Humans ; Child ; Chromosome Aberrations ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/pathology
    Language English
    Publishing date 2022-12-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2022017409
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top